Combined BRAF/AurkA inhibition might offer a therapeutic alternative to BRAF/MEK inhibition for BRAF-mutated melanomas, while a combination of MEK/AurkA inhibitors could represent a possible option for patients without BRAF mutations. This evidence concerns the gene BRAF and melanoma.